ADAM12 is expressed in the tumour vasculature and mediates ectodomain shedding of several membrane-anchored endothelial proteins
- 25 April 2013
- journal article
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 452 (1) , 97-109
Abstract
ADAM (a disintegrin and metalloproteinase) 12 is a metalloprotease implicated in cancer progression. ADAM12 can activate membrane-anchored proteins, such as sonic hedgehog, Delta-like 1 and certain epidermal growth factor receptor ligands, through a process called ectodomain shedding. We screened several membrane-anchored proteins to further dissect the substrate profile of ADAM12-mediated ectodomain shedding, and found shedding of five previously unreported substrates [Kitl1, VE-cadherin (vascular endothelial cadherin), Flk-1 (fetal liver kinase 1), Tie-2, and VCAM-1 (vascular cell adhesion molecule 1)], of which the latter four are specifically expressed by endothelial cells. We also observed that ADAM12 expression was increased in the tumour vasculature of infiltrating ductal carcinoma of the human breast as compared with little to no expression in normal breast tissue vasculature, suggesting a role for ADAM12 in tumour vessels. These results prompted us to further evaluate ADAM12-mediated shedding of two endothelial cell proteins, VE-cadherin and Tie-2. Endogenous ADAM12 expression was very low in cultured endothelial cells, but was significantly increased by cytokine stimulation. In parallel, the shed form of VE-cadherin was elevated in such cytokine-stimulated endothelial cells, and ADAM12 siRNA (small interfering RNA) knockdown reduced cytokine-induced shedding of VE-cadherin. In conclusion, the results of the present study demonstrate a role for ADAM12 in ectodomain shedding of several membrane-anchored endothelial proteins. We speculate that this process may have importance in tumour neovascularization or/and tumour cell extravasation.Keywords
This publication has 57 references indexed in Scilit:
- An essential role of metalloprotease-disintegrin ADAM12 in triple-negative breast cancerBreast Cancer Research and Treatment, 2012
- Potential of fluorescent metalloproteinase substrates for cancer detectionClinical Biochemistry, 2011
- Shedding of Cell Membrane-Bound Proteoglycans2011
- ADAM12 Transmembrane and Secreted Isoforms Promote Breast Tumor GrowthJournal of Biological Chemistry, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Selective inhibition of ADAM12 catalytic activity through engineering of tissue inhibitor of metalloproteinase 2 (TIMP-2)Biochemical Journal, 2010
- The Role of SnoN in Transforming Growth Factor β1-induced Expression of Metalloprotease-Disintegrin ADAM12Journal of Biological Chemistry, 2010
- ADAM8 is a negative regulator of retinal neovascularization and of the growth of heterotopically injected tumor cells in miceJournal of Molecular Medicine, 2010
- ADAM9 Is Involved in Pathological Retinal NeovascularizationMolecular and Cellular Biology, 2009
- VEGF receptor signalling ? in control of vascular functionNature Reviews Molecular Cell Biology, 2006